These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26312831)

  • 1. Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of TP53 mutation and therapeutic implications.
    Wilkie M; Lau A; Vlatkovic N; Jones T; Boyd M
    Lancet; 2015 Feb; 385 Suppl 1():S101. PubMed ID: 26312831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.
    Sandulache VC; Skinner HD; Ow TJ; Zhang A; Xia X; Luchak JM; Wong LJ; Pickering CR; Zhou G; Myers JN
    Cancer; 2012 Feb; 118(3):711-21. PubMed ID: 21720999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines.
    Wilkie MD; Anaam EA; Lau AS; Rubbi CP; Vlatkovic N; Jones TM; Boyd MT
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
    Wilkie MD; Lau AS; Vlatkovic N; Jones TM; Boyd MT
    Oral Oncol; 2018 Aug; 83():1-10. PubMed ID: 30098763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies.
    Wilkie MD; Anaam EA; Lau AS; Rubbi CP; Jones TM; Boyd MT; Vlatković N
    Cancer Lett; 2020 May; 478():107-121. PubMed ID: 32113989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
    Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
    Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of mutations within the TP53 gene in patients with squamous cell carcinoma of the head and neck].
    Golusinski P; Lamperska K; Pazdrowski J; Golusinski W
    Otolaryngol Pol; 2011; 65(2):114-21. PubMed ID: 21735667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.
    Lindenbergh-van der Plas M; Brakenhoff RH; Kuik DJ; Buijze M; Bloemena E; Snijders PJ; Leemans CR; Braakhuis BJ
    Clin Cancer Res; 2011 Jun; 17(11):3733-41. PubMed ID: 21467160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.
    Harami-Papp H; Pongor LS; Munkácsy G; Horváth G; Nagy ÁM; Ambrus A; Hauser P; Szabó A; Tretter L; Győrffy B
    Oncotarget; 2016 Oct; 7(41):67183-67195. PubMed ID: 27582538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of
    Kealey J; Düssmann H; Llorente-Folch I; Niewidok N; Salvucci M; Prehn JHM; D'Orsi B
    Front Cell Dev Biol; 2022; 10():893677. PubMed ID: 36238683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
    Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
    Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times.
    Eriksen JG; Alsner J; Steiniche T; Overgaard J
    Radiother Oncol; 2005 Aug; 76(2):135-42. PubMed ID: 16024113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-7 expression in serous ovarian carcinomas.
    Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
    Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
    Artman T; Schilling D; Gnann J; Molls M; Multhoff G; Bayer C
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):574-82. PubMed ID: 20117293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.
    Xu L; Pirollo KF; Tang WH; Rait A; Chang EH
    Hum Gene Ther; 1999 Dec; 10(18):2941-52. PubMed ID: 10609655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-dependent radiosensitivity: clonogenic survival, apoptosis and cell-cycle redistribution.
    Williams JR; Zhang Y; Zhou H; Russell J; Gridley DS; Koch CJ; Little JB
    Int J Radiat Biol; 2008 Feb; 84(2):151-64. PubMed ID: 18246483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines.
    Godoy PR; Mello SS; Magalhães DA; Donaires FS; Nicolucci P; Donadi EA; Passos GA; Sakamoto-Hojo ET
    Mutat Res; 2013 Aug; 756(1-2):46-55. PubMed ID: 23817105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck.
    Younes MN; Yigitbasi OG; Yazici YD; Jasser SA; Bucana CD; El-Naggar AK; Mills GB; Myers JN
    Arch Otolaryngol Head Neck Surg; 2007 Jan; 133(1):15-23. PubMed ID: 17224516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.